(±)-CP 55,940-d11 is intended for use as an internal standard for the quantification of (±)-CP 55,940 by GC- or LC-MS. (±)-CP 55,940 is a potent, non-selective cannabinoid (CB) receptor agonist (Kis = 5 and 1.8 nM for human CB1 and CB2, respectively).1 It stimulates [35S]GTPγS binding to rat cerebellar membranes (EC50s = 0.22-0.96 nM).2 In vivo, (±)-CP 55,940 induces analgesia in the tail clamp, hot plate, tail flick, flinch jump, and PBQ-induced writhing tests with 50% maximum possible effect (MPE50) values of 0.46, 1.11, 0.55, 0.63, and 0.29 mg/kg, respectively.3 (±)-CP 55,940 also decreases the discrimination index (DI) of female, but not male, rats in the object location task as well as the DI of male, but not female, rats in the novel object recognition task.4
1.Pertwee, R.G.Pharmacology of cannabinoid receptor ligandsCurr. Med. Chem.6(8)635-664(1999) 2.Griffin, G., Atkinson, P.J., Showalter, V.M., et al.Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranesJ. Pharmacol. Exp. Ther.285(2)553-560(1998) 3.Howlett, A.C., Johnson, M.R., Melvin, L.S., et al.Nonclassical cannabinoid analgetics inhibit adenylate cyclase: Development of a cannabinoid receptor modelMol. Pharmacol.33(3)297-302(1987) 4.Mateos, B., Borcel, E., Loriga, R., et al.Adolescent exposure to nicotine and/or the cannabinoid agonist CP 55,940 induces gender-dependent long-lasting memory impairments and changes in brain nicotinic and CB1 cannabinoid receptorsJ. Psychopharmacol.25(12)1676-1690(2011)